C.Y. Cheng, chairman and president of Formosa Laboratories, shares exciting news about the establishment of a new drug development company, Formosa Pharmaceuticals. He explains how the know-how gained from running a successful international API production business will help Formosa avoid the typical mistakes that young R&D companies face.
Mr. Cheng, when we met you back in 2013 you noted that government and industry have to work together to make Taiwan more modern and more international. What main ‘biotech achievements’ have you observed on the island since then?
"More than 95 percent of our clients are international, mainly coming from the US or focusing on the US market."
